搜尋結果
2012年1月10日 · Latest Health News. Strokes Are Increasing in People Under 65 While elderly people still have more strokes than other age groups, a new CDC study shows an increase in strokes among younger people ...
- Treatment
- Benefits
- Results
For some people with severe or hard-to-treat depression, electroconvulsive therapy (ECT) is the best treatment. This treatment, sometimes referred to as \"electroshock therapy,\" is often misunderstood and incorrectly portrayed by popular media as a harsh, cruel treatment. In reality, it is a painless medical procedure performed under general anest...
With ECT, an electrical stimulation is delivered to the brain and causes a seizure. For reasons that doctors don't completely understand, this seizure helps relieve the symptoms of depression. ECT does not cause any structural damage to the brain.
Studies have shown that ECT works for many people who have treatment-resistant depression. One study of 39 people with treatment-resistant depression compared the effects of an antidepressant with ECT. After two to three weeks, 71% of people who received ECT had a positive response to treatment. But only 28% who received the antidepressant had a po...
2023年5月22日 · A typical aPTT value is 30 to 40 seconds. If you get the test because you’re taking heparin, you’d want your PTT results to be more like 120 to 140 seconds, and your aPTT to be 60 to 80 ...
2023年3月23日 · Overview. Ashwagandha is an evergreen shrub that grows in Asia and Africa. It is commonly used for stress. There is little evidence for its use as an "adaptogen." Ashwagandha contains chemicals ...
2024年2月27日 · One showed that taking 2.4 grams per day reduced LDL levels by 22% and total cholesterol by 16% in 12 weeks. Another study showed that taking 1.2 grams per day lowered LDL levels by 26% in just 8 ...
2024年3月19日 · Heel spurs. Another source of foot pain, heel spurs are abnormal growths of bone on the bottom of your heel. You can get them from wearing the wrong shoes, an abnormal walk or posture, or even ...
2022年10月3日 · The meningococcal conjugate vaccine or MCV4 was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's immune cells ...
